There are 14 papers on atrophic vaginitis in aging research: 3 trials and 3 observational studies in people, 1 in animals, 5 reviews.
See all 26 papers on atrophic vaginitis
“TGFA (OR: 0.880, 95% CI: 0.790-0.981) were inversely associated with PAV risk.”
- Human trial3
- Humans3
- Animals1
Associations
4IL10RA
downin humans1OR 0.906
1 study
IL10RA
downin humans1OR 0.906
IL10RA is linked with a lower risk of atrophic vaginitis in humans (OR: 0.906, 95% CI: 0.831-0.988).
“IL10RA (OR: 0.906, 95% CI: 0.831-0.988), and TGFA (OR: 0.880, 95% CI: 0.790-0.981) were inversely associated with PAV risk.”
Humans
International journal of women's health
IL12B
upin humans1OR 1.05
1 study
IL12B
upin humans1OR 1.05
IL12B is linked with a higher risk of atrophic vaginitis in humans (OR: 1.050, 95% CI: 1.002-1.100).
“IL12B (OR: 1.050, 95% CI: 1.002-1.100) were associated with increased PAV risk”
Humans
International journal of women's health
CCL19
upin humans1OR 1.063
1 study
CCL19
upin humans1OR 1.063
CCL19 is linked with a higher risk of atrophic vaginitis in humans (OR: 1.063, 95% CI: 1.003-1.126).
“CCL19 (OR: 1.063, 95% CI: 1.003-1.126) and IL12B (OR: 1.050, 95% CI: 1.002-1.100) were associated with increased PAV risk”
Humans
International journal of women's health
TGFA
downin humans1OR 0.88
1 study
TGFA
downin humans1OR 0.88
TGFA is linked with a lower risk of atrophic vaginitis in humans (OR: 0.880, 95% CI: 0.790-0.981).
“TGFA (OR: 0.880, 95% CI: 0.790-0.981) were inversely associated with PAV risk.”
Humans
International journal of women's health
Trial sponsors
Company1 trialPhase 3535 people
Company1 trialPhase 3366 people
Company1 trialPhase 116 people
Company1 trial130 people
1 trialPhase 4110 people
AGUNCO Obstetrics and Gynecology Centre
1 trialPhase 4
1 trialPhase 1100 people
First Affiliated Hospital, Sun Yat-Sen University
1 trialPhase 180 people